论文部分内容阅读
目的:探讨Brn-3a和MDM-2在宫颈癌和癌前病变中的表达及其作为宫颈癌和癌前病变生物标志物的可行性和临床意义。方法:利用SP免疫组化法检测110例蜡块标本中Brn-3a和MDM-2的表达。结果:宫颈癌及癌前病变各组的Brn-3a表达阳性率均高于对照组,差异有统计学意义(P<0.05);SCC组及CINIII组的MDM-2表达阳性率均高于对照组,差异有统计学意义(P<0.05),SCC组与CIN组比较,差异有统计学意义(P<0.05)。Brn-3a和MDM-2在各临床分期及组织学分级中的阳性表达无统计学差异(P>0.05);Brn-3a与MDM-2蛋白阳性表达之间无相关关系(P>0.05)。结论:Brn-3a和MDM-2可作为宫颈癌前病变的生物标志物。
Objective: To investigate the expression of Brn-3a and MDM-2 in cervical cancer and precancerous lesions and their feasibility and clinical significance as biomarkers of cervical cancer and precancerous lesions. Methods: The expression of Brn-3a and MDM-2 in 110 specimens of wax blocks was detected by SP immunohistochemistry. Results: The positive rates of Brn-3a in cervical cancer and precancerous lesions were higher than those in control group (P <0.05). The positive rates of MDM-2 in SCC group and CINIII group were higher than those in control group Group, the difference was statistically significant (P <0.05), SCC group and CIN group, the difference was statistically significant (P <0.05). The positive expression of Brn-3a and MDM-2 in clinical stage and histological grade showed no significant difference (P> 0.05). There was no correlation between Brn-3a and MDM-2 protein expression (P> 0.05). Conclusion: Brn-3a and MDM-2 can be used as biomarkers of cervical precancerous lesions.